News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–16
Matches
16
Sources here
7
Companies here
1
Search results Stored financial headlines

Active search

16 matching headlines

Ticker or company: XLOMain company stories
Clear
Latest

Stock Titan Deals and strategy

StemPoint group (XLO) discloses 9.5% Xilio Therapeutics stake via warrants

StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross have collectively reported a 9.5% beneficial ownership in Xilio Therapeutics, Inc. (XLO) through an SEC Schedule 13G/A filing. Their stake comprises 628,866 shares of common stock, primarily derived from pre-funded, Series A, and Series C warrants, all subject to a 9.99% beneficial ownership limitation. This disclosure indicates …

Main company 🇺🇸 United States
Read at Stock Titan
Sharemaestro market context Trend signal active 52 weeks -6.8% · Next-week setup negative 45.0% XLO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Just inNext headlines
MarketBeat Earnings Main company 🇺🇸 United States

Xilio Therapeutics (NASDAQ:XLO) Announces Earnings Results, Beats Estimates By $0.26 EPS

Xilio Therapeutics (NASDAQ:XLO) announced its earnings results, reporting an adjusted loss of $0.33 per share, which beat analyst estimates by $0.26. The company's revenue of $18.69 million also surpassed expectations, though Xilio Therapeutics remains unprofitable with a negative net margin. Despite institutional investor ownership …

XLO main company
Sharemaestro market context Trend signal active 52 weeks -6.8% · Next-week setup negative 45.0% XLO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
AlphaStreet Earnings Main company 🇺🇸 United States

Xilio Therapeutics Releases Q2 2026 Financial Results

Xilio Therapeutics (XLO) reported its Q2 2026 financial results, showing a narrower net loss of $0.33 per share, an 85.3% improvement year-over-year. Revenue significantly increased by 131.2% to $18.7 million compared to Q2 2025. The company specializes in tumor-activated immuno-oncology therapies and continues to …

XLO main company
Sharemaestro market context Trend signal active 52 weeks -6.8% · Next-week setup negative 45.0% XLO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Investing.com Nigeria Market update Main company 🇺🇸 United States

Form 8K Xilio Therapeutics Inc For: 12 August By Investing.com

This article reports on Xilio Therapeutics Inc.'s Form 8K filing for August 12. It notes the company's stock symbol as XLO, which saw a -1.42% change. The content primarily serves as a placeholder or announcement regarding the SEC filing.

XLO main company
Sharemaestro market context Trend signal active 52 weeks -6.8% · Next-week setup negative 45.0% XLO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Xilio Therapeutics reports Q2 2026: $18.7M collaboration revenue, $6.4M net loss, cash $136.0M

Xilio Therapeutics reported its Q2 2026 financial results, showing $18.7 million in collaboration revenue and a net loss of $6.4 million. The company held $136.0 million in cash and cash equivalents, expecting this to fund operations into Q1 2028. Key business highlights include FDA …

XLO main company
Sharemaestro market context Trend signal active 52 weeks -6.8% · Next-week setup negative 45.0% XLO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

Xilio expects to dose cancer patients with XTX501 in H2 2026

Xilio Therapeutics reported its Q2 2026 financial results and provided updates on its pipeline, including FDA clearance for XTX501, a bispecific PD-1 / masked IL-2, with dosing expected in H2 2026. The company also announced advancing IND-enabling studies for two masked T cell engager …

XLO main company
Sharemaestro market context Trend signal active 52 weeks -6.8% · Next-week setup negative 45.0% XLO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Xilio Therapeutics Inc (XLO) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Xilio Therapeutics Inc (XLO), noting its strong buy rating from analysts and its top ranking in the Biotechnology & Medical Research industry. It details expected revenue for the next quarter, price targets, and past and future EPS …

XLO main company
Sharemaestro market context Trend signal active 52 weeks -6.8% · Next-week setup negative 45.0% XLO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

XLO Q2'26 Earnings: revenue estimate is 12.72M USD

Xilio Therapeutics, Inc. (XLO) is scheduled to release its Q2'26 earnings on August 12, with an estimated revenue of $12.72 million and an anticipated EPS of ($0.59). The article provides historical revenue and EPS data, including reported figures, estimates, and surprise percentages for previous …

XLO main company
Sharemaestro market context Trend signal active 52 weeks -6.8% · Next-week setup negative 45.0% XLO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Xilio Therapeutics Inc (XLO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Xilio Therapeutics Inc (XLO), focusing on its support and resistance levels, key indicators, and moving averages. The stock is currently trading between a resistance level of 9.92 and a support level of 8.34, suggesting suitability for range-bound …

XLO main company
Sharemaestro market context Trend signal active 52 weeks -6.8% · Next-week setup negative 45.0% XLO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Xilio Therapeutics Inc (XLO) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Xilio Therapeutics Inc (XLO), highlighting its current valuation score and P/E ratio. The company's valuation score is 9.76, placing it 10th in the Biotechnology & Medical Research industry, with a P/E ratio of -0.16. The report notes …

XLO main company
Sharemaestro market context Trend signal active 52 weeks -6.8% · Next-week setup negative 45.0% XLO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Xilio Therapeutics Inc (XLO) Financial Health: Profitability & Balance Sheet Analysis

The article provides an analysis of Xilio Therapeutics Inc's (XLO) financial health, noting its current financial score of 7.95, ranking 73 out of 385 in the Biotechnology & Medical Research industry. The company shows stable financial status and high operating efficiency, with significant year-over-year …

XLO main company
Sharemaestro market context Trend signal active 52 weeks -6.8% · Next-week setup negative 45.0% XLO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

XLO|Xilio Therapeutics Inc|Price:9.150|Chg%:+0.060

Xilio Therapeutics Inc (XLO) shows relatively healthy fundamentals, high growth potential, and strong institutional ownership. Its valuation is considered fair within the Biotechnology & Medical Research industry, ranking 39 out of 384. Analysts have issued a "Strong Buy" rating with a target price of …

XLO main company
Sharemaestro market context Trend signal active 52 weeks -6.8% · Next-week setup negative 45.0% XLO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Xilio Therapeutics Inc (XLO) Cash Flow

This article provides a detailed quarterly and annual cash flow statement for Xilio Therapeutics Inc (XLO), allowing users to evaluate the company's financial health. It breaks down operating, investing, and financing cash flows, along with historical data and year-over-year changes. The piece also includes …

XLO main company
Sharemaestro market context Trend signal active 52 weeks -6.8% · Next-week setup negative 45.0% XLO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Xilio Therapeutics Inc (XLO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Xilio Therapeutics Inc (XLO), showing its current stock price, market cap, and P/E. It details revenue by region, specifically highlighting the United States, but notes that relevant data for business segments and current fiscal years have not …

XLO main company
Sharemaestro market context Trend signal active 52 weeks -6.8% · Next-week setup negative 45.0% XLO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

TradingKey

This article provides a detailed quarterly and annual income statement for Xilio Therapeutics Inc. (XLO), including total revenue, operating expenses, net income, and EPS data from Q1 2020 to Q1 2026. It also includes FAQs explaining how to interpret the income statement and defining …

XLO main company
Sharemaestro market context Trend signal active 52 weeks -6.8% · Next-week setup negative 45.0% XLO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Yahoo! Finance Canada Earnings Main company 🇺🇸 United States

Xilio Therapeutics, Inc. (XLO) Stock Price, News, Quote & History

This page provides comprehensive financial information for Xilio Therapeutics, Inc. (XLO), including its current stock price, recent news, historical data, and analyst insights. The company is a clinical-stage biotechnology firm focused on developing masked immuno-oncology therapies. Key financial metrics, performance overview, and comparisons with …

XLO main company
Sharemaestro market context Trend signal active 52 weeks -6.8% · Next-week setup negative 45.0% XLO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context